Goldman Sachs Group Inc. boosted its position in Exactech, Inc. (NASDAQ:EXAC) by 7.7% during the first quarter, Holdings Channel reports. The institutional investor owned 36,617 shares of the medical equipment provider’s stock after buying an additional 2,612 shares during the period. Goldman Sachs Group Inc.’s holdings in Exactech were worth $923,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. State Street Corp increased its position in shares of Exactech by 11.3% in the fourth quarter. State Street Corp now owns 245,639 shares of the medical equipment provider’s stock worth $6,707,000 after buying an additional 25,011 shares in the last quarter. Rice Hall James & Associates LLC increased its position in shares of Exactech by 74.1% in the first quarter. Rice Hall James & Associates LLC now owns 99,270 shares of the medical equipment provider’s stock worth $2,502,000 after buying an additional 42,256 shares in the last quarter. Thomson Horstmann & Bryant Inc. purchased a new position in shares of Exactech during the first quarter worth about $4,857,000. Kirr Marbach & Co. LLC IN increased its position in shares of Exactech by 1.2% in the first quarter. Kirr Marbach & Co. LLC IN now owns 10,760 shares of the medical equipment provider’s stock worth $271,000 after buying an additional 125 shares in the last quarter. Finally, Wells Fargo & Company MN increased its position in shares of Exactech by 13.0% in the first quarter. Wells Fargo & Company MN now owns 57,447 shares of the medical equipment provider’s stock worth $1,448,000 after buying an additional 6,590 shares in the last quarter. Institutional investors own 64.05% of the company’s stock.

Shares of Exactech, Inc. (EXAC) remained flat at $28.05 on Monday. The company had a trading volume of 2,718 shares. The company has a 50-day moving average of $29.63 and a 200-day moving average of $27.97. Exactech, Inc. has a 12 month low of $22.20 and a 12 month high of $31.90. The stock has a market capitalization of $402.46 million, a PE ratio of 539.42 and a beta of 1.02.

Exactech (NASDAQ:EXAC) last issued its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.33 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.33. Exactech had a net margin of 7.25% and a return on equity of 7.96%. The company had revenue of $67.30 million during the quarter, compared to the consensus estimate of $67.75 million. During the same quarter last year, the company earned $0.31 earnings per share. Exactech’s revenue for the quarter was up 1.8% on a year-over-year basis. Equities analysts anticipate that Exactech, Inc. will post $1.29 earnings per share for the current fiscal year.

WARNING: This article was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another site, it was illegally copied and reposted in violation of US and international copyright legislation. The correct version of this article can be read at https://www.watchlistnews.com/goldman-sachs-group-inc-purchases-2612-shares-of-exactech-inc-exac/1487493.html.

EXAC has been the subject of a number of recent research reports. Zacks Investment Research upgraded shares of Exactech from a “sell” rating to a “hold” rating in a research note on Tuesday, April 25th. TheStreet upgraded shares of Exactech from a “c+” rating to a “b” rating in a research note on Tuesday, April 25th. BidaskClub downgraded shares of Exactech from a “hold” rating to a “sell” rating in a research note on Monday, July 31st. Finally, Gabelli reiterated a “buy” rating on shares of Exactech in a research note on Monday, July 31st.

In other Exactech news, Director William B. Locander sold 988 shares of the stock in a transaction that occurred on Wednesday, May 31st. The shares were sold at an average price of $30.34, for a total value of $29,975.92. Following the completion of the sale, the director now owns 8,555 shares of the company’s stock, valued at $259,558.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Joel C. Phillips sold 7,610 shares of the stock in a transaction that occurred on Tuesday, May 23rd. The shares were sold at an average price of $30.71, for a total transaction of $233,703.10. Following the completion of the sale, the chief financial officer now directly owns 99,907 shares of the company’s stock, valued at approximately $3,068,143.97. The disclosure for this sale can be found here. Insiders sold 10,358 shares of company stock valued at $314,311 in the last ninety days. 28.30% of the stock is owned by corporate insiders.

About Exactech

Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines.

Want to see what other hedge funds are holding EXAC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exactech, Inc. (NASDAQ:EXAC).

Institutional Ownership by Quarter for Exactech (NASDAQ:EXAC)

Receive News & Ratings for Exactech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exactech Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.